Viral Associations in Multiple Sclerosis and Other Neurodegenerative Conditions
A systematic review found strong temporal evidence linking Epstein-Barr virus (EBV) to multiple sclerosis (MS). The review evaluated viral involvement in various diseases, though it noted limitations in firmly establishing EBV's role in MS progression.
- Most relevant to
- Neurologist, Immunologist
Why it matters
Understanding the relationship between EBV and MS could provide insights into disease mechanisms and potential therapeutic targets. However, it does not prove causation or clarify how EBV might influence established MS.
What this does not prove
The review does not confirm that herpesviruses initiate Alzheimer's or that ongoing EBV activity affects established MS.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-15
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceViral Links to Neurodegenerative Diseases ↗
Supporting passages (6)
study designThis review evaluates evidence for viral involvement in disease initiation, modification of established disease, impaired viral control secondary to disease or treatment, and incidental detection.
findingsThe strongest temporal evidence concerns Epstein-Barr virus (EBV) and MS.
limitationsHowever, evidence that ongoing EBV activity modifies established MS remains limited.
findingsProspective data place EBV seroconversion before clinical onset and the first observed increase in serum neurofilament light chain, while mechanistic studies link EBV infection, B-cell biology, and CNS-directed immunity.
findingsStronger inference across these diseases will require longitudinal studies relating viral activity and antiviral immunity to subsequent disease-related changes, together with intervention studies that document the intended effect on the implicated viral process and separately assess subsequent disease risk or progression.
publication datePublication date: 2026-09-15
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.